Los Angeles Capital Management LLC Has $282,000 Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX)

Los Angeles Capital Management LLC lowered its position in MeiraGTx Holdings plc (NASDAQ:MGTX) by 51.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,370 shares of the company’s stock after selling 48,990 shares during the quarter. Los Angeles Capital Management LLC’s holdings in MeiraGTx were worth $282,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Privium Fund Management B.V. grew its stake in shares of MeiraGTx by 4.9% in the 3rd quarter. Privium Fund Management B.V. now owns 213,960 shares of the company’s stock valued at $892,000 after buying an additional 10,000 shares in the last quarter. Royce & Associates LP lifted its stake in MeiraGTx by 5.3% in the third quarter. Royce & Associates LP now owns 795,392 shares of the company’s stock valued at $3,317,000 after acquiring an additional 40,000 shares during the last quarter. BNP Paribas Financial Markets grew its position in MeiraGTx by 142.5% in the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock worth $39,000 after acquiring an additional 5,476 shares in the last quarter. Knoll Capital Management LLC acquired a new position in shares of MeiraGTx during the 3rd quarter worth $5,212,000. Finally, Erste Asset Management GmbH bought a new position in shares of MeiraGTx during the 3rd quarter valued at $2,795,000. 67.48% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other MeiraGTx news, CEO Alexandria Forbes sold 35,839 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the sale, the chief executive officer now owns 1,395,102 shares of the company’s stock, valued at $9,026,309.94. This trade represents a 2.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total value of $150,960.00. Following the transaction, the chief financial officer now owns 849,947 shares of the company’s stock, valued at approximately $5,346,166.63. This trade represents a 2.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on MGTX shares. Royal Bank of Canada upped their price objective on shares of MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and set a $36.00 price target on shares of MeiraGTx in a research note on Monday, February 24th.

MeiraGTx Price Performance

Shares of MeiraGTx stock opened at $6.68 on Wednesday. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. The firm has a fifty day simple moving average of $6.44 and a 200-day simple moving average of $5.69. The stock has a market capitalization of $522.06 million, a price-to-earnings ratio of -5.52, a PEG ratio of 0.37 and a beta of 1.23. MeiraGTx Holdings plc has a 1-year low of $3.85 and a 1-year high of $7.80.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.